The stock's overall trend over the past six months has been volatile but ultimately negative, with the price declining from approximately $27.32 in early October 2025 to $26.94 as of March 31, 2026, representing a 6-month change of -1.39%. In the short term, the stock has shown relative strength, gaining 1.35% over the last three months while the S&P 500 (SPY) fell 4.63%, but it declined 0.22% over the past month. The current price of $26.94 sits near the middle of its 52-week range of $24.14 to $34.99, approximately 23% above the low and 23% below the high, indicating a neutral position within its annual trading band.

Revenue growth has been positive, with a year-over-year increase of 12.33% for the quarter ending December 31, 2025, and net income for that quarter was a strong $123 million. Profitability metrics are healthy, with trailing net and operating margins of 12.48% and 16.28%, respectively. Financial health is a concern due to a high debt-to-equity ratio of 134.24 and a weak current ratio of 0.63, though operating cash flow for the latest quarter was a robust $239.9 million. Operational efficiency shows a solid return on equity (ROE) of 13.03%, but the trailing twelve-month free cash flow is negative at -$20.96 million, indicating significant capital expenditure.